A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Clinical success rate
研究概览
简要总结
Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease
详细描述
The medical records, demographic characteristics and clinical data of patients with invasive fungal disease treated with amphotericin B or azoles were collected through the electronic medical record system of Sichuan Provincial People's Hospital from 2021 to 2024. To evaluate the efficacy and safety of these two types of drugs.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •There is no age limit, gender is not limited
- •Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.
排除标准
- •Patients with incomplete data or other factors affecting the clinical outcome judgement
- •Patients who are judged by the investigator to be unsuitable to participate in this study.
结局指标
主要结局
Clinical success rate
时间窗: The end of treatment, up to 1 year
Clinical success incudes cure or symptom improvement，which means patients are alive, IFD-related symptoms and signs, radiographic abnormalities improve or disappear completely, and microbiological evidence suggests fungal clearance. The proportion of patients with cured or improved symptoms in the total population was analyzed.
次要结局
- Safety of amphotericin B and azoles(During the treatment (1-14 days); the end of treatment (Day 14);Day 28 after the start of treatment)
研究者
Lingai Pan
Deputy Chief Physician
Sichuan Provincial People's Hospital